| Stathmin-2 (SCG10) | |
|---|---|
| Protein Name | Stathmin-2 |
| Gene | STMN2 |
| UniProt | Q93045 |
| PDB Structures | No full-length structure available; stathmin-like domain modeled |
| Molecular Weight | ~20.8 kDa (179 amino acids) |
| Localization | Growth cones, axonal vesicles, Golgi membranes |
| Protein Family | Stathmin family (STMN1-4) |
Stathmin 2 (Scg10) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Stathmin-2 (also known as SCG10, Superior Cervical Ganglion 10) is a neuron-enriched phosphoprotein of the stathmin family that plays a critical role in axonal growth, maintenance, and regeneration. Encoded by the [STMN2[/genes/stmn2 gene on chromosome 8q21.13, stathmin-2 is one of the most abundantly expressed proteins in [motor neurons[/cell-types/motor-neurons and is essential for axonal repair after injury (Klim et al., 2019). Stathmin-2 has become the focus of intense therapeutic development following the discovery that its loss — through cryptic splicing of STMN2 mRNA upon [TDP-43[/proteins/tdp-43 nuclear depletion — is a major pathogenic mechanism in [amyotrophic lateral sclerosis (ALS)[/diseases/als, [Frontotemporal Dementia (FTD)[/diseases/ftd, and other [TDP-43 proteinopathies]. The first-in-class therapeutic QRL-201 (Quralis), an antisense oligonucleotide designed to restore stathmin-2 expression, entered clinical trials in 2023 and has shown early signals of disease modification in ALS patients.
Stathmin-2 is a 179-amino-acid protein (~20.8 kDa) with three functional domains:
Stathmin-2 undergoes several functionally important modifications:
As a stathmin family member, stathmin-2 can regulate microtubule dynamics by sequestering free tubulin dimers and promoting microtubule depolymerization. However, unlike stathmin (STMN1), stathmin-2 is membrane-associated and concentrated in specific subcellular compartments (growth cones, vesicles) rather than distributed throughout the cytoplasm. This localized regulation of microtubule dynamics is important for growth cone steering and axonal branching.
Stathmin-2 is essential for motor axon regeneration after injury. Following peripheral nerve damage, stathmin-2 expression is rapidly upregulated in injured motor [neurons[/entities/neurons, and the protein is transported to regenerating growth cones. Mice lacking stathmin-2 show impaired motor axon regeneration, delayed functional recovery, and defective reinnervation of neuromuscular junctions (Guerra San Juan et al., 2023).
Importantly, stathmin-2's role in promoting axon regeneration appears to be independent of its tubulin-binding capacity, suggesting it acts through alternative mechanisms — possibly involving membrane trafficking, signaling at the growth cone, or interactions with other cytoskeletal regulators (Bhola et al., 2025).
During embryonic development, stathmin-2 is highly expressed in the developing nervous system, where it contributes to axon outgrowth and pathfinding. It is one of the earliest markers of neuronal differentiation and is expressed before neurite extension begins. Expression persists throughout adult life in mature [neurons[/entities/neurons, where stathmin-2 is concentrated in axonal terminals and growth cone-like structures, maintaining ongoing capacity for synaptic remodeling and injury response.
The central pathogenic mechanism linking stathmin-2 to neurodegeneration involves [TDP-43[/proteins/tdp-43 (encoded by [TARDBP). Under normal conditions, [TDP-43[/entities/tdp-43 binds to a GU-rich sequence in intron 1 of [STMN2[/genes/stmn2 pre-mRNA, blocking a cryptic splice-polyadenylation site. When [TDP-43[/entities/tdp-43 is depleted from the nucleus — as occurs in >97% of [ALS[/diseases/als cases and ~45% of [FTD[/diseases/ftd cases — this cryptic site is activated, producing a truncated mRNA that encodes only 17 amino acids instead of the full 179-amino-acid stathmin-2 protein (Baughn et al., 2023).
The resulting near-complete loss of functional stathmin-2 in affected [neurons[/entities/neurons ablates their capacity for axonal maintenance and regeneration, contributing to progressive neurodegeneration. STMN2 is the most affected RNA target of [TDP-43[/entities/tdp-43 loss-of-function, and processing of STMN2 pre-mRNA is more sensitive to [TDP-43[/entities/tdp-43 depletion than [UNC13A[/proteins/unc13a, the other major cryptic splicing target, making stathmin-2 restoration a prime therapeutic strategy (Krus et al., 2022).
[UNC13A[/proteins/unc13a is the second major TDP-43 cryptic splicing target. While STMN2 cryptic exon inclusion affects axonal maintenance, UNC13A cryptic splicing disrupts synaptic vesicle release at the presynaptic terminal. Both STMN2 and UNC13A cryptic exon transcripts are detected in post-mortem tissue from patients with TDP-43 pathology, and their co-occurrence is a hallmark of TDP-43-associated neurodegeneration (Agra Almeida Quadros et al., 2024). Loss of TDP-43 induces synaptic dysfunction that can be rescued by UNC13A splice-switching ASOs, complementing the axonal rescue afforded by STMN2 restoration, suggesting that dual targeting of both cryptic exons may be necessary for optimal therapeutic efficacy.
In [ALS[/diseases/als, stathmin-2 protein is dramatically reduced in spinal cord motor [neurons[/entities/neurons with TDP-43 pathology. The truncated stathmin-2 peptide (first 16 amino acids + 1 cryptic residue) can serve as a neuropathological marker of TDP-43 dysfunction, and truncated STMN2 mRNA has been detected in CSF, positioning it as a potential fluid biomarker for TDP-43 Proteinopathy status (Melamed et al., 2019). In [FTD[/diseases/ftd with TDP-43 pathology (FTLD-TDP), stathmin-2 loss occurs in affected frontal and temporal [cortex[/brain-regions/cortex regions. The degree of STMN2 cryptic exon inclusion correlates with the severity of TDP-43 pathology and clinical disease burden.
Cryptic splicing of STMN2 has been detected in [Alzheimer's disease[/diseases/alzheimers patients with TDP-43 co-pathology (~30-50% of AD cases), correlating with TDP-43 pathology burden but not with [Amyloid-Beta[/proteins/Amyloid-Beta or tau[/proteins/tau-protein deposits (Agra Almeida Quadros et al., 2024). This finding suggests that STMN2 cryptic splicing may contribute to the motor and cognitive deficits seen in the substantial subset of AD patients who harbor concurrent TDP-43 pathology (limbic-predominant age-related TDP-43 encephalopathy, or LATE).
STMN2 cryptic splicing has also been detected in:
Detection of truncated STMN2 mRNA or cryptic exon-containing transcripts in cerebrospinal fluid (CSF) is under active development as a biomarker for TDP-43 proteinopathies. Unlike neurofilament light chain (NfL), which reflects generalized neurodegeneration, STMN2 cryptic exon products would be specific to TDP-43 dysfunction, enabling:
In post-mortem tissue, immunohistochemical detection of truncated stathmin-2 protein provides a sensitive marker of TDP-43 pathology, complementing TDP-43 immunostaining and potentially revealing early-stage pathology before overt TDP-43 inclusions form.
In post-mortem tissue, immunohistochemical detection of truncated stathmin-2 protein provides a sensitive marker of TDP-43 pathology, complementing TDP-43 immunostaining and potentially revealing early-stage pathology before overt TDP-43 inclusions form.
QRL-201 (Quralis Corporation) is a first-in-class antisense oligonucleotide (ASO) targeting the STMN2 cryptic splice site to restore full-length stathmin-2 expression in patients with ALS. QRL-201 is delivered by intrathecal injection and blocks the cryptic exon inclusion that occurs when TDP-43 is depleted from the nucleus.
ANQUR Clinical Trial (Phase 1/2): The ANQUR study is a double-blind, placebo-controlled clinical trial that has enrolled a total of 69 patients across dose escalation (n=17) and dose range-finding (DRF, n=52) phases:
QRL-201 represents the first clinical program in sporadic ALS to show potential restoration of STMN2 expression, combined with evidence of target engagement and signals of disease modification.
A gene therapy approach using engineered small nuclear RNAs (snRNAs) has been developed to simultaneously correct cryptic splicing of both STMN2 and UNC13A from a single AAV vector. In iPSC-derived motor neurons with TDP-43 knockdown, dual-targeting snRNAs restored normal STMN2 pre-mRNA processing and rescued stathmin-2 protein levels while also correcting UNC13A splicing. This approach addresses the theoretical limitation of ASOs that target only one cryptic exon, as both STMN2 and UNC13A contribute to motor neuron dysfunction through distinct but complementary mechanisms (axonal maintenance and synaptic transmission, respectively).
The CRISPR effector dCasRx has been used to block STMN2 cryptic splicing in TDP-43-deficient human motor neurons, providing proof-of-concept for RNA-targeted gene therapy. This approach uses catalytically inactive Cas13d to sterically block the cryptic splice site without cleaving the mRNA, preserving the native transcript while preventing aberrant processing.
AAV-mediated overexpression of STMN2 is under investigation as an alternative approach to bypass the cryptic splicing defect entirely by providing exogenous stathmin-2 from a delivered transgene. This strategy would restore stathmin-2 regardless of TDP-43 status but requires achieving appropriate expression levels in target motor neurons.
Several factors complicate STMN2-directed therapy:
[Proteins Index[/proteins
[Axonal Transport[/mechanisms/axonal-transport-defects
[amyotrophic lateral sclerosis[/diseases/als
[Parkinson's disease[/diseases/parkinsons
The study of Stathmin 2 (Scg10) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.